South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals
The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity.
Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore.
The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three.
% Female board level representation by country |
|
France |
43.8% |
UK |
36.0% |
Australia |
34.0% |
Germany |
32.5% |
Spain |
29.8% |
US |
29.8% |
South Africa |
28.5% |
Singapore |
17.3% |
India |
17.0% |
The public sector – meaning members of Parliament or equivalent – is faring slightly better. The average across the countries surveyed is 33.2% - a marginal difference compared to the private sector – but two thirds (6 out of 9) countries showed more promising gender parity in their governments compared to on their boards. South Africa led the way in the public sector with 44% of its MPs being women – a huge step up from its 28.5% parity at board level – though France is the most gender-diverse nation when taking an average across both its parliament and the boards of its largest companies. The average across both sectors is 32% female representation, whereas France is a leader with 40.4% parity overall.
% Female parliament representation by country |
|
South Africa |
44.0% |
Spain |
42.0% |
Australia |
38.0% |
France |
37.0% |
UK |
34.0% |
Germany |
33.0% |
Singapore |
30.0% |
US |
27.0% |
India |
14.0% |
This year’s annual report demonstrates modest progress compared with 2020. Representation of women in the private sector has increased marginally in the United States (1.2%), United Kingdom (3%) and Australia (0.6%), as well as in the parliaments in Australia (1%) and the United States (3.5%), which had a record year for women elected. India remains the least gender diverse country studied with representation of women under 20% across both public (14%) and private sectors (17%).
Beth Sehgal, global director of diversity, equity, and inclusion at Kearney, comments:
“It’s positive to see businesses and governments move towards equal representation as women hold an increasing number of high-ranking positions. However, progress has been slow, and the gender leadership gap endures. France is leading the way for private sector representation and South Africa ranks number one for public sector diversity, and the progress of these two countries should provide benchmarks as we work towards achieving gender parity worldwide.
“Diversity, Equity and Inclusion initiatives will need to be prioritized, particularly in countries lagging behind. Diversity has regularly been linked to high-performance with a variety of perspectives encouraging fresh ideas and preventing the dreaded group think. As the economy rebuilds from the aftermath of coronavirus, it will be crucial women are fairly represented in both public and private sector roles to help assist in its recovery and to avoid a regression on gender equality or “she-cession”.”
About Kearney
As a global consulting partnership in more than 40 countries, our people make us who we are. We’re individuals who take as much joy from those we work with as the work itself. Driven to be the difference between a big idea and making it happen, we help our clients break through. Learn more at Kearney.com.
About the research
Kearney‘s Gender Equality Report 2021 was based on research using publicly available data across nine countries – UK, US, France, Germany, Spain, Australia, India and Singapore – regarding the representation of women at board level and in their respective parliaments. Board information was gathered using the support of Factset.
Read the report: https://www.kearney.com/web/international-womens-day/article/?/a/the-equality-dilemma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005622/en/
Contact information
Press contact
Sophie Mellish
Rostrum – PR consultants to Kearney
s.mellish@rostrum.agency
+44 7789 712 597
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 08:30:00 EEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including prioritisation of sharehol
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 04:00:00 EEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 22:32:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom